Liquid biopsies represent a revolutionary approach to cancer diagnostics, offering a non-invasive alternative to tissue biopsies. By analyzing circulating tumor DNA (ctDNA), exosomes, and other biomarkers in blood, liquid biopsies enable early detection, real-time monitoring, and treatment adjustments. They are particularly valuable for cancers with challenging biopsy procedures, such as pancreatic and lung cancers. Research focuses on enhancing sensitivity and specificity, developing multi-cancer detection platforms, and integrating liquid biopsies into routine care. These advancements hold immense potential to transform cancer management, offering hope for improved outcomes.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China